ACI-24.060 at Dose B

Biologic

AAC Immune SA

ACI-24.060 at Dose B is one of 33 biologic programs targeting Down syndrome. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Down SyndromeActive, not recruiting

Down SyndromePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Down Syndrome

#DrugCompanyPhaseTrials

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 2

Wellcovorin

GGlaxo Dba Glaxosmithkline

Keppra

1 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Aricept

Eisai

Phase 3

2 6

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

—7

Donepezil Hydrochloride

Eisai

Phase 3

1 8

Folinic Acid

Roche

Phase 3

1 9

Namenda

AbbVie

Phase 2

2 10

Quillivant XR

Pfizer

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Amyloid Plaque

NCT05462106

Clinical

Trials by Indication[1]

Amyloid Plaque1 trial

A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)

Recruiting·AAC Immune SA·Preclinical·NCT05462106·304 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ACI-24.060 at Dose B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACI-24.060 at Dose B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACI-24.060 at Dose B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AC Immune SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: AAC Immune SA

ACI-24.060 at Dose B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Amyloid Plaque1 trial

References

Drug Info

Quick Facts

Related News